The conception and production of conjugate vaccines using recombinant DNA technology

BioPharm International

Volumn 25, Issue 1, 2012, Pages 28-32

  Gambillara, Veronica ^a  

^a GlycoVacyn   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIAL VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE;

ARTICLE; BACTERIAL IMMUNITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MARKETING; DRUG PURIFICATION; DRUG PURITY; DRUG SAFETY; INFECTION PREVENTION; NONHUMAN; PROCESS DEVELOPMENT; PRODUCT DEVELOPMENT; RECOMBINANT DNA TECHNOLOGY; VACCINATION; VACCINE PRODUCTION;

EID: 84859070228     PISSN: 1542166X     EISSN: 19391862     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (14)

1. Datamonitor, Pneumococcal and Meningococcal Vaccines: Market Forecast (Datamonitor, 2010).
2. O.T. Avery and W. F. Goebel, J. Exp. Med. 50 (4), 521-533 (1929).
3. M. Kowarik et al., EMBO J. 25 (9), 1957-1966 (2006).
4. M. Wacke et. al., Science 298 (5599), 1790-1793 (2002).
5. T.D. Bugg and P. E. Brandish, FEMS Microbiol. Lett. 119 (3), 255-262 (1994).
6. M.F. Feldman et al., Proc. Natl. Acad. Sci. 102 (8), 3016-3021 (2005).
7. M. Wacker et al., Proc. Natl. Acad. Sci. 103 (18), 7088-7093 (2006).
8. J.B. Robbins, C. Chu, and R. Schneerson, Clin. Infect. Dis. 15 (2), 346-361 (1992).
9. J.B. Robbins et al., Proc. Natl. Acad. Sci. 106 (19), 7974-7978 (2009).
10. M.M. Levine et al., J. Infect. Dis. 127 (3), 261-270 (1973).
11. M.M. Levine et al., N. Engl. J. Med. 288 (22), 1169-1171 (1973).
12. J.C. Lee, Curr. Infect. Dis. Rep. 3 (6), 517-524 (2001).
13. G.L. Archer, Clin Infect Dis 26, 1179-1181 (1998).
14. J.C. Lee et al., presentation at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL, 2011).